Undisclosed SMARCA2 Degrader / Dr. Reddy’s, Aurigene - LARVOL DELTA

Discovery and characterization of once in a month intravenous and orally bioavailable SMARCA2 degraders for treating SMARCA4 mutant cancers (AACR 2026) - "We report the identification and preclinical development of highly potent and selective SMARCA2 degraders based on rational design by optimizing assemblies of SMARCA2/4 bromodomain binders, degron-linking moieties, and ligands for specific E3 ligases...Furthermore, the lead degrader exhibited robust antitumor efficacy in multiple SMARCA4-deficient CDX models at well-tolerated doses. Repeat-dose tolerability studies in non-rodent species are ongoing to support candidate nomination by Q4 2025."

Oncology • SMARCA2 • SMARCA4

Discovery of highly selective, potent and orally bio-available SMARCA2 degraders (AACR 2025) - "Here, we report the identification and development of highly selective SMARCA2 degrader with oral bioavailability that have demonstrated robust efficacy in SMARCA4 mutant CDX models...Further, the identified degrader demonstrated robust efficacy supported by SMARCA2 degradation in multiple SMARCA4-mutant CDX models, at well-tolerated doses. Repeat dose tolerability profile of the lead compound in non-rodent species is ongoing towards candidate nomination."

Oncology • SMARCA2 • SMARCA4